Detalhe da pesquisa
1.
New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
J Drugs Dermatol;
19(6): 602-610, 2020 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32574011
2.
Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
J Drugs Dermatol;
19(3): 272-279, 2020 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32549090
3.
Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials
J Drugs Dermatol;
19(1): 70-77, 2020 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31985914
4.
Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.
J Drugs Dermatol;
19(11): 1086-1092, 2020 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33196747
5.
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
J Drugs Dermatol;
19(9): 867-872, 2020 Sep 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33026753
6.
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
J Drugs Dermatol;
18(3): 279-284., 2019 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30909333
7.
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
J Drugs Dermatol;
18(3): 297-299, 2019 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30909352
8.
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris
J Drugs Dermatol;
18(6): 542, 2019 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31251546
9.
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
J Am Acad Dermatol;
78(1): 81-89.e5, 2018 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28985956
10.
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
J Am Acad Dermatol;
79(2): 287-293, 2018 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29614243
11.
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis
J Drugs Dermatol;
17(12): 1290-1296, 2018 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30586261
12.
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol;
17(7): 723-726, 2018 Jul 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30005093
13.
Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
J Drugs Dermatol;
17(10): 1084-1091, 2018 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30365589
14.
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
J Drugs Dermatol;
17(8): 863-868, 2018 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30124725
15.
Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
J Drugs Dermatol;
17(10): 1062-1069, 2018 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30365586
16.
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
J Drugs Dermatol;
17(8): 855-861, 2018 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30124724
17.
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
J Drugs Dermatol;
16(3): 197-204, 2017 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28301614
18.
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.
J Am Acad Dermatol;
84(4): 1140-1142, 2021 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32622145
19.
Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a 21-Day Treatment Period.
J Drugs Dermatol;
15(6): 721-6, 2016 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27272079
20.
Randomized, Double-Blind, Split-Face Study to Compare the Irritation Potential of Two Topical Acne Formulations Over a 21-Day Treatment Period.
J Drugs Dermatol;
15(2): 178-82, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26885785